Grifols Acquires 60 Percent Stake in Progenika | GenomeWeb

NEW YORK (GenomeWeb News) – Barcelona-based plasma products manufacturer Grifols has acquired a 60 percent stake in Progenika Biopharma for €37 million ($48.4 million), the firms announced earlier this week.

Grifols paid 50 percent of the consideration in cash, with the other 50 percent coming in the form of non-voting (Class B) Grifols shares.

Vizcaya, Spain-based Progenika develops molecular diagnostics tests and DNA chips for disease diagnosis and prognosis. In particular, it has developed tests for evaluating transfusional compatibility studies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.